Mycobacterium Patents (Class 435/253.1)
  • Patent number: 10077461
    Abstract: A method for characterizing at least one microorganism from a sample includes identifying the at least one microorganism and determining the properties of typing, potential resistance to at least one antimicrobial, and virulence factor. The properties of typing, resistance to at least one antimicrobial, and virulence factor for the at least one microorganism are determined by implementing mass spectrometry using proteins, peptides and/or metabolites as markers of the properties of typing, resistance to at least one antimicrobial, and virulence factor.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: September 18, 2018
    Assignee: BIOMERIEUX S.A.
    Inventors: Corinne Beaulieu, Yannick Charretier, Jean-Philippe Charrier, Sonia Chatellier, Philippe Dufour, Christine Franceschi, Victoria Girard, Sylvie Pons
  • Patent number: 9751834
    Abstract: The present invention relates to oxygenated amino or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives, in particular the compounds of formula 1, 2, 3, 4, 5 or 6, and their medical use, including their use in the treatment, prevention or amelioration of an inflammatory, autoimmune and/or allergic disorder, or a proliferative, neoplastic or dysplastic disease or disorder.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: September 5, 2017
    Assignee: GRI BIO, INC.
    Inventors: Georg Schlechtingen, Hans-Joachim Knölker, Tim Friedrichson, Gary Jennings, Tobias Braxmeier
  • Patent number: 9139809
    Abstract: The invention is directed compositions and methods related to bacterial cells physically associated with ceramide-like glycolipids. The invention allows for delivery of ceramide-like glycolipid adjuvants directly to the same cells that become infected with a bacterial vaccine. The compositions and methods of the present invention are useful for the prevention and treatment of diseases.
    Type: Grant
    Filed: January 8, 2010
    Date of Patent: September 22, 2015
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Steven A. Porcelli, Manjunatha M. Venkataswamy
  • Patent number: 8992942
    Abstract: The present invention is directed to reagents useful for generating immune responses to Mycobacterium tuberculosis and for diagnosing infection and disease in a subject that has been exposed to M. tuberculosis.
    Type: Grant
    Filed: August 4, 2011
    Date of Patent: March 31, 2015
    Assignee: Rutgers, The State University of New Jersey
    Inventor: Maria Laura Gennaro
  • Publication number: 20150071873
    Abstract: A first and a second identical or different mycobacterial immunogenic compositions, each comprising at least a Mycobacterium bovis bacillus Calmette-Guerin (BCG), an antigenically related non-pathogenic mycobacteria, or one or more immunogenic component(s) thereof, as therapeutic active ingredient(s) for use in the treatment of cancer by parenteral or oral administration of the first composition to a cancer patient before local administration of the second composition at tumor site. A method in vitro for monitoring cancer treatment by immunotherapy with BCG, antigenically related non-pathogenic mycobacteria, or immunogenic component(s) thereof, comprising assaying BCG-specific immune response in a patient.
    Type: Application
    Filed: January 24, 2013
    Publication date: March 12, 2015
    Inventors: Claire Biot, Matthew Albert, Cyrill Rentsch, Joel Gsponer
  • Patent number: 8974798
    Abstract: Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: March 10, 2015
    Assignee: Zoetis P&U LLC
    Inventors: David E. Lowery, Troy E. Fuller, Michael J. Kennedy
  • Patent number: 8932846
    Abstract: Recombinant immunogenic compositions, and methods for the manufacture and use, are provided for the prevention and treatment of intracellular pathogen diseases in humans and animals. The recombinant immunogenic compositions express high levels of recombinant proteins in vectors that do not harbor an antibiotic resistance marker (“unmarked”).
    Type: Grant
    Filed: June 12, 2008
    Date of Patent: January 13, 2015
    Assignee: The Regents of the University of California
    Inventors: Marcus A. Horwitz, Michael V. Tullius
  • Patent number: 8932608
    Abstract: Provided is a pharmaceutical composition that includes one or more inactivated Mycobacterium spp., which are preferably inactivated using gamma irradiation, and which is than formulated for mucosal or pulmonary delivery to a subject. The pharmaceutical compositions are useful for preventing or treating mycobacterium-associated infections in a subject, including a human subject.
    Type: Grant
    Filed: February 11, 2013
    Date of Patent: January 13, 2015
    Assignee: Mico Bio, Inc.
    Inventors: Jason Fisher, Jennifer Lighter
  • Patent number: 8932851
    Abstract: The present invention relates to an improved culture medium and method for the enhanced growth and detection of Mycobacterium growth. The invention further relates to an improved mycobacterial reagent system or kit that can be used for the enhanced growth and detection of Mycobacterium.
    Type: Grant
    Filed: January 15, 2013
    Date of Patent: January 13, 2015
    Assignee: bioMērieux, Inc.
    Inventors: Parampal Deol, Leticia Barton, Yoany Portilla, Douglas Lovern
  • Patent number: 8865422
    Abstract: A method for the diagnosis of a tuberculosis infection caused by Mycobacteria belonging to the Mycobacteria tuberculosis complex group (MTC) in an animal including a human being, which comprises in vitro-detection of cell-mediated immune response to OmpAtb and/or antibodies against OmpAtb in a sample taken from that animal.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: October 21, 2014
    Assignee: Prionics AG
    Inventors: Bruno Oesch, Irene Schiller, Martin Vordermeier
  • Publication number: 20140308317
    Abstract: The present disclosure provides compounds, or pharmaceutically acceptable salts thereof, for inhibiting the growth of a microbe; treating a mammal having a microbial infection, malaria, mucositis, an ophthalmic infection, an otic infection, a cancer, or a Mycobacterium infection; killing or inhibiting the growth of a Plasmodium species; inhibiting the growth of a Mycobacterium species; modulating an immune response in a mammal; or antagonizing unfractionated heparin, low molecular weight heparin, or a heparin/low molecular weight heparin derivative.
    Type: Application
    Filed: December 9, 2013
    Publication date: October 16, 2014
    Applicant: CELLCEUTIX CORPORATION
    Inventors: Xiaodong Fan, Yongjiang Xu, Dahui Liu, Michael J. Costanzo
  • Patent number: 8846372
    Abstract: The use of free, extractable lipids found in bacteria for identification of bacterial species and subspecies is described. Bacteria have been found to differ sufficiently in their extracted lipid compositions to effect identification using thin layer chromatographic techniques. Burkholderia pseudomallei, Burkholderia thailandensis, and Burkholderia mallei have been distinguished in this manner. Lipopeptides specific to Mycobacterium avium subspecies paratuberculosis, but not to the closely related bacterium Mycobacterium avium subspecies avium have also been used as a basis for bacterial subspecies identification using mass spectrometry and seroreactivity.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: September 30, 2014
    Assignee: Colorado State University Research Foundation
    Inventors: Torsten Manfred Eckstein, Julia Mitsue Inamine Eckstein
  • Patent number: 8841432
    Abstract: The present disclosure provides a DNA molecule capable of replication in Mycobacteria having a nucleic acid sequence as disclosed in SEQ ID NO: 1, a shuttle vector constructed using it and a transformed cells containing the present vector. The vector of about 18 kb of the present disclosure contains 16 ORFs, a replication origin and a rep-like protein essential for replication. Therefore, the plasmid of the present disclosure can be utilized as a gene delivery system/research, and also in a therapeutic system such as immune therapeutics by effectively delivering proteins or heterologous DNA and expressing the encoded DNA in cells.
    Type: Grant
    Filed: April 19, 2012
    Date of Patent: September 23, 2014
    Assignee: SNU R&DB Foundation
    Inventors: Bum-Joon Kim, Hyungki Lee
  • Publication number: 20140271719
    Abstract: Described herein is a mycobacterium mutant, comprising at least one mutation in at least one gene sequence encoding global gene regulators (GGRs) selected from the group consisting of sigH, sigL, sigE, ECF-1, and mixtures thereof, wherein the GGR gene is at least partially inactivated. Described herein also is a vaccine based on the mutant and a method of differentiating between subjects that have been infected with mycobacterium and subjects that have not been infected with mycobacterium or have been vaccinated with a mycobacterium vaccine.
    Type: Application
    Filed: February 28, 2014
    Publication date: September 18, 2014
    Applicant: Wisconsin Alumni Research Foundation
    Inventor: Adel M. Talaat
  • Patent number: 8835619
    Abstract: The present invention is directed to heat shock proteins from Mycobacterium leprae as well as their encoding polynucleotides and vectors and host cells containing these polynucleotides. These heat shock proteins and their encoding polynucleotides are useful in detection of Mycobacterium leprae. In addition, the heat shock protein can be used as an adjuvant in a pharmaceutical composition containing an antigen to induce or enhance the immune response against the antigen. Further, the heat shock protein may be used to treat atopic conditions or as a vaccine against Mycobacterium leprae. Alternatively, the heat shock protein can be used to form a fusion protein with an antigen to induce or enhance the immune response against the antigen.
    Type: Grant
    Filed: November 23, 2009
    Date of Patent: September 16, 2014
    Assignee: New York University
    Inventors: William R. Levis, Frank T. Martiniuk
  • Patent number: 8795978
    Abstract: Methods for screening for agents that modulate the activation state, i.e., active growth or persistence, of Mycobacterium tuberculosis (Mtb), methods of treating an Mtb infection in a subject using agents identified by the screening methods, and methods for screening for a latent Mtb infection in a subject are disclosed. The screening methods involve contacting a Mtb sensor kinase with an agent to be tested, then detecting the response of the Mtb sensor kinase to modulating ligands or detecting changes in the oxidation state of the heme iron of the Mtb sensor kinase. The methods for treating an Mtb infection in a subject involve administering a therapeutically effective amount of an agent identified by the screening methods. The methods for screening for a latent Mtb infection in a subject involve detecting carbon monoxide or nitric oxide binding to heme iron of Mtb sensor kinases.
    Type: Grant
    Filed: June 20, 2008
    Date of Patent: August 5, 2014
    Assignee: The UAB Research Foundation
    Inventors: Adrie J. C. Steyn, Ashwani Kumar
  • Patent number: 8758773
    Abstract: A composition and method for immunizing a mammal infected with Mycobacterium are disclosed. The genes gcpE, pstA, kdpC, papA2, impA, umaA1, fabG2_2, aceAB, mbtH2, lpqP, map0834c, cspB, lipN, and map1634 of M. paratuberculosis and the products that they encode are vaccine targets for Johne's and Crohn's disease. Eighteen M. paratuberculosis-specific genomic islands (MAPs) were identified. Three inverted large genomic fragments in M. paratuberculosis (INV) were also identified. These genomic identifiers represent novel virulence determinants that can be used as targets for vaccines and for developments of drugs against Johne's disease. The methods can be used to deliver an immunizing compound to a mammal, to provide an immune response against Johne's or Crohn's disease in the mammal.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: June 24, 2014
    Assignee: Wisconsin Alumni Research Foundation
    Inventor: Adel Mohamed Talaat
  • Publication number: 20140171444
    Abstract: The present invention provides aryl- or heteroaryl-diketo acid compounds effective to inhibit an activity of a Mycobacterial malate synthase enzyme or to inhibit a malate synthase activity in other bacteria having the enzyme. The compounds may be phenyl- naphthyl-, or thienyl-substituted diketo acids and carboxylate derivatives thereof. Also provided are methods of treating tuberculosis or other pathophysiological conditions associated with a malate synthase enzyme with the inhibitory compounds and methods of in silico design of the inhibitory compounds. In addition, the present invention provides the inhibitory compounds designed by this method. Furthermore, three-dimensional X-ray crystal structures of the Mycobacterial malate synthase complexed with the inhibitory compounds are provided. Further still a method for stabilizing an aromatic or heteroaromatic diketo acid or its prodrug or close analog in solution by derivatizing at least the ortho position on the aromatic ring is provided.
    Type: Application
    Filed: March 3, 2014
    Publication date: June 19, 2014
    Applicant: THE TEXAS A&M UNIVERSITY SYSTEM
    Inventors: Joel S. Freundlich, James C. Sacchettini, Inna V. Kriger, Thomas R. Ioerger, Vijay Gawandi
  • Patent number: 8735091
    Abstract: The present invention is directed to a method for inactivation and/or extraction of acid-fast bacteria (e.g., mycobacteria or nocardia), the method comprising the following sequential steps: (a) acquiring a test sample known to contain or that may contain acid-fast bacteria and suspending the test sample in a container containing ethanol and beads; (b) bead beating and/or vortexing the container to break up clumps and/or disrupt acid-fast bacteria cells in the container; and (c) subsequently incubating the suspension for at least about 3 minutes at room temperature to inactivate any acid-fast bacteria contained in the test sample. In accordance with the present invention, the test sample can subsequently be pelleted by centrifugation, resuspended with formic acid, acetonitrile added, and subjected to mass spectrometry for characterization and/or identification of the acid-fast bacteria.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: May 27, 2014
    Assignee: BioMerieux, Inc.
    Inventors: Jones M. Hyman, Parampal Deol, Elizabeth Miller, Victoria Girard, Amber Gates, Sandrine Mailler, Maud Arsac, John Walsh
  • Publication number: 20140057272
    Abstract: A method of culturing fastidious bacteria where a conditioned cell culture medium is prepared in which eukaryotic cells have been cultured, but where the medium is substantially free of the cultured cells. Fastidious bacteria are cultured in the medium. The conditioned cell culture medium can contain secreted factors from the cells. These factors promote the growth of the fastidious bacteria. The fastidious bacterial culture is maintained for a time period sufficient for the fastidious bacteria to multiply. The fastidious bacteria are analyzed using PCR, DNA sequencing or microbiology characterization.
    Type: Application
    Filed: August 21, 2013
    Publication date: February 27, 2014
    Applicant: MRIGlobal
    Inventors: Kelly Brown, Richard Winegar, Jacqueline Bortzner, Nicole Moritz, Stephanie Sorrell
  • Publication number: 20140037700
    Abstract: Disclosed are methods and compositions for treating or preventing microbial infections.
    Type: Application
    Filed: April 19, 2012
    Publication date: February 6, 2014
    Applicant: MICO BIO, INC.
    Inventor: Jason Fisher
  • Patent number: 8617871
    Abstract: The present invention relates to an improved culture medium and method for the enhanced growth and detection of Mycobacterium growth. The invention further relates to an improved mycobacterial reagent system or kit that can be used for the enhanced growth and detection of Mycobacterium.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: December 31, 2013
    Assignee: bioMerieux, Inc.
    Inventors: Parampal Deol, Leticia Barton, Yoany Portilla, Douglas Lovern
  • Publication number: 20130323208
    Abstract: Invention is using M. brumae is a mycobacterium strain which stimulates immune system cells strongly, is non-pathogen for humans and has all of the defining attributes of the strain with catalog number 51384, American Type Culture Collection (ATCC) for therapy of superficial bladder cancers.
    Type: Application
    Filed: December 20, 2011
    Publication date: December 5, 2013
    Inventors: Naciye Leyla Açan, Abdurrahim Haluk Özen, Esra Büber, Zühtü Tanil Kocagöz, Zeliha Ertürk, Zehra Stara Yüksel, Mehmet Selçuk Keskin, Bagnu Orhan, Alpaslan Alp, Zeynep Saribas
  • Publication number: 20130295648
    Abstract: The present invention relates to increase in survival of mammals suffering from desmocollin 3 expressing cancers. Mycobacterium w is administered to mammals suffering from desmocollin-3 expressing cancers. The administration of Mycobacterium w results in control of tumor and improvement in survival. Mycobacterium w can also be used along with other therapeutic agent(s)/modalities as per the requirement. The squamous type of non small cell lung cancer is known to be desmocollin-3 expressing cancer. Other cancers also express desmocollin-3.
    Type: Application
    Filed: January 10, 2012
    Publication date: November 7, 2013
    Inventors: Bakulesh Mafatlal Khamar, Indravadan Ambalal Modi
  • Publication number: 20130288340
    Abstract: An object of the present invention is to provide a microorganism which is novel at the elemental composition level, and to provide a technique for providing such a microorganism. The present inventor has succeeded in causing a microorganism to efficiently contain a non-essential element by decreasing the content of an essential nutrient source for the microorganism, a C source, an N source, a P source, or an S source, and by adding an X compound containing the non-essential element as a constitutive element in a manner to make up for the decreased amount, and then culturing the microorganism.
    Type: Application
    Filed: September 5, 2011
    Publication date: October 31, 2013
    Applicants: PARA MICROBIOS LABORATORIES LLC
    Inventor: Yoshitake Tanaka
  • Patent number: 8518663
    Abstract: In various embodiments, the invention relates to a method for identifying the presence of particular bacteria in a sample. The method includes collecting a sample that includes or has been exposed to the particular bacteria and detecting, in the sample, at least one volatile organic compound indicative of the presence of the bacteria.
    Type: Grant
    Filed: April 27, 2010
    Date of Patent: August 27, 2013
    Assignee: The Charles Stark Draper Laboratory, Inc.
    Inventors: Jose M. Trevejo, Preshious Rearden
  • Patent number: 8507251
    Abstract: The present invention provides a growth medium and kit containing a nicotine analog and use of the same in a method for enhancing the growth of Mycobacterium avium subspecies paratuberculosis (MAP).
    Type: Grant
    Filed: September 28, 2010
    Date of Patent: August 13, 2013
    Inventor: Robert J. Greenstein
  • Publication number: 20130202642
    Abstract: Methods of preparing mutants of Mycobacterium tuberculosis with one or more disrupted genes are presented, where the disrupted genes include ctpV, rv0990c, rv0971c, and/or rv0348. Compositions containing mutants with attenuated virulence and pathogenesis, which are capable of stimulation of an immune response against tuberculosis, are described. Compositions and methods relating to immunogenic compositions, which include an attenuated M. tb strain in which the M. tb genome includes a disruption of at least one of the ctpV gene, the rv0990c gene, the rv0971c gene, and the rv0348 gene, are also provided.
    Type: Application
    Filed: January 3, 2013
    Publication date: August 8, 2013
    Inventors: Adel M. Talaat, Sarah K. Ward, Bassam Abomoelak
  • Patent number: 8481056
    Abstract: Whole-cell vaccines and methods for their use in producing protective immune responses in vertebrate hosts subsequently exposed to pathogenic bacteria. The present invention involves a method of enhancing antigen presentation by intracellular bacteria in a manner that improves vaccine efficacy. After identifying an enzyme that has an anti-apoptotic effect upon host cells infected by an intracellular microbe, the activity of the enzyme is reduced, thereby modifying the microbe so that it increases immunogenicity. Also, the present invention provides a method of incrementally modifying enzyme activity to produce incrementally attenuated mutants of the microbe from which an effective vaccine candidate can be selected.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: July 9, 2013
    Assignee: Vanderbilt University
    Inventors: Douglas S. Kernodle, Markian R. Bochan
  • Publication number: 20130164329
    Abstract: The present invention relates to compositions and methods for isolating cells devoid of unwanted viral contaminants, and to methods for preparing a virus stock substantially devoid of viral contaminants. Virus stocks, cells, and immunogenic reagents produced using such methods are also provided.
    Type: Application
    Filed: February 16, 2011
    Publication date: June 27, 2013
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Anthony Rossomando, John M. Maraganore, Stuart Pollard, Muthiah Manoharan
  • Publication number: 20130164325
    Abstract: The invention is directed compositions and methods related to bacterial cells that are physically associated with ceramide-like glycolipids for use as antigen carriers for heterologous antigens. The invention further relates to methods of incorporating ceramide-like glycolipid to bacterial cell walls. The compositions and methods of the present invention are useful for the prevention and treatment of diseases.
    Type: Application
    Filed: July 6, 2011
    Publication date: June 27, 2013
    Applicant: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Steven A. Porcelli, Manjunatha M. Venkataswamy
  • Patent number: 8465753
    Abstract: The invention relates to a combination vaccine against Mycobacterium avium subspecies paratuberculosis (MAP) and M. tuberculosis and/or M. bovis for use in methods of immunizing a subject against mycobacterial infection, preventing or treating mycobacterial infection, and preventing a disease associated with mycobacterial infection.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: June 18, 2013
    Inventor: Robert J. Greenstein
  • Publication number: 20130142828
    Abstract: The present invention relates to novel mycobacterial compositions containing RNA and cell walls, and methods for making and using these compositions. These compositions have immune stimulating and anti-cancer activity. The present invention also relates to a synthetic medium for the cultivation of mycobacteria.
    Type: Application
    Filed: October 13, 2011
    Publication date: June 6, 2013
    Applicant: Bioniche Urology IP Inc.
    Inventors: Nigel C. Phillips, Danbing Ke, Zdenek Richard Holan, Mario C. Filion, Mohamed Elrafih, Iqubal Velji
  • Patent number: 8445662
    Abstract: The present invention is related to a M. tuberculosis fusion protein, polynucleotide coding for said protein, and a vector and host cell that contain said polynucleotide. The present invention also involves the preparation of said fusion protein, and the use thereof in preventions and treatment of tuberculosis.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: May 21, 2013
    Assignees: The 309th Hospital, The People's Liberation Army, Yangzhou Yilin Biotechnology Co., Ltd
    Inventors: Xiuyun He, Yuhui Zhuang, Haibin Wang, Jianhua Tao
  • Publication number: 20130101623
    Abstract: The present invention provides a novel attenuated vaccine for tuberculosis. Furthermore, when used as a subcutaneous vaccine, the present invention induces a higher level of protection than the current vaccine. Finally, the present invention results in less tissue damage and a lower number of colony forming units (CFU) in the lungs compared to subjects vaccinated with BCG.
    Type: Application
    Filed: October 3, 2012
    Publication date: April 25, 2013
    Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
    Inventor: UNIVERSITY OF MEDICINE AND DENTISTRY OF
  • Patent number: 8426580
    Abstract: The present invention relates to the design of the Antisense-oligonucleotide complementary to the specific region of peptide deformylase gene from Mycobacterium tuberculosis. The use of this Antisense-oligonucleotide on mycobacterial culture inhibits the production of the peptide deformylase enzyme by hybridizing within the region, which is found to be responsible for maintaining stability as well as retaining the functionality of the enzyme and thus in turn affecting the growth of the cells. This invention also establishes the essentiality of the peptide deformylase enzyme in mycobacteria and claims it as a drug target in this microorganism.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: April 23, 2013
    Assignee: Council of Scientific and Industrial Research
    Inventors: Rahul Saxena, Pardip K. Chakraborti
  • Patent number: 8394388
    Abstract: Provided are recombinant mycobacteria having a mutation in an nlaA gene or in a nuoG gene. Also provided are isolated and purified nlaA proteins and nuoG proteins from a mycobacterium. Additionally provided are isolated and purified nucleic acids comprising a recombinant nlaA gene or a recombinant nuoG gene. Further provided are methods of inducing an immune response in a mammal and methods of making a recombinant mycobacterium using the nlaA gene or the nuoG gene.
    Type: Grant
    Filed: January 12, 2006
    Date of Patent: March 12, 2013
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: William R. Jacobs, Jr., Steven A. Porcelli, Volker Briken, Miriam Braunstein
  • Publication number: 20130059364
    Abstract: The present invention relates to a culture medium for disperse mycobacteria comprising at least one detergent and an antifoam agent, whereby said antifoam agent is a member of the silicone family. In addition, the invention provides for methods for the activation of dipressed mycobacteria, for obtaining a standardized mycobyterial culture or for the production of (a), purified protein derivates(s) (PDD) which comprise the cultivation of mycobacteria in the active medium disclosed herein. Furthermore, the use of standardized mycobacterial cultures obtained by the method of the invention for the preparation of pharmaceutical or diagnostic compositions is described.
    Type: Application
    Filed: July 3, 2012
    Publication date: March 7, 2013
    Applicant: Novartis Vaccines and Diagnostics GmbH
    Inventors: Guido Dietrich, Erika Hundt, Heinz Weber
  • Patent number: 8389267
    Abstract: The present invention relates to an improved culture medium and method for the enhanced growth and detection of Mycobacterium growth. The invention further relates to an improved mycobacterial reagent system or kit that can be used for the enhanced growth and detection of Mycobacterium.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: March 5, 2013
    Assignee: bioMérieux, Inc.
    Inventors: Parampal Deol, Leticia Barton, Yoany Portilla, Douglas Lovern
  • Patent number: 8389268
    Abstract: The present invention relates to an improved culture medium and method for the enhanced growth and detection of Mycobacterium growth. The invention further relates to an improved mycobacterial reagent system or kit that can be used for the enhanced growth and detection of Mycobacterium.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: March 5, 2013
    Assignee: bioMérieux, Inc.
    Inventors: Parampal Deol, Leticia Barton, Yoany Portilla, Douglas Lovern
  • Publication number: 20130040829
    Abstract: A method of inducing latency in Mycobacterium permits preparation of an in vitro model system of latent mycobacterial infection. Latency is induced in a pure culture of Mycobacterium by exposing it to multiple stress conditions, including a low nutrient culture medium without glycerol, a low pH, a relatively high level of carbon dioxide and a relatively low gas phase oxygen level. An in vitro model of mycobacterial infection employs macrophages induced from THP1 cells which are then infected with Mycobacterium. The infected macrophages are grown under hypoxic conditions to induce latency in the mycobacteria. The in vitro model of infection is useful in evaluating compounds for activity against latent mycobacteria.
    Type: Application
    Filed: August 13, 2012
    Publication date: February 14, 2013
    Applicant: University of Central Florida Research Foundation, Inc.
    Inventors: Pappachan E. Kolattukudy, Tatiana Sirakova, Jaiyanth Daniel, Chirajoti Deb
  • Publication number: 20120329138
    Abstract: A process for separation of a mixture containing a microbial substance and a liquid using deformable filter is provided.
    Type: Application
    Filed: December 19, 2011
    Publication date: December 27, 2012
    Applicant: SHELL OIL COMPANY
    Inventors: Henry Van Kaathoven, Johannes Pieter Haan, Wilhelmus Maria Bond, Johannes Leendert Willem Cornelis Den Boestert
  • Patent number: 8283136
    Abstract: This invention relates to Micrococcus luteus containing compositions useful for controlling skin disorders in which bacteria are a causative component. The invention also provides for a new strain of Micrococcus luteus useful in these compositions.
    Type: Grant
    Filed: February 23, 2010
    Date of Patent: October 9, 2012
    Assignee: Blis Technologies Limited
    Inventors: John Robert Tagg, Christopher Norman Chilcott, Mohammed Abdullah Ali Alqumber
  • Patent number: 8268581
    Abstract: Compositions and methods are provided that are useful for predicting and controlling the stability of expressed polypeptides. The compositions and methods may be used to predict and as desired, increase or decrease the stability of proteins recombinantly expressed in mycobacteria, for example DesA3 expressed in Mycobacterium smegmatis. At the C terminus and the penultimate position, substitution to residues with charged side chains, large non-polar side chains, or no side chains can be used to reduce or inhibit the protein degradation. At the antepenultimate position from the C terminus, residues with no side chain or acidic side chains can increase the stability, i.e. reduce or inhibit the protein degradation. The combinational substitution of only the last three residues of polypeptides can make the polypeptides more stable during heterologous expression in mycobacterial hosts.
    Type: Grant
    Filed: April 28, 2009
    Date of Patent: September 18, 2012
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Brian G. Fox, Yong Chang, Gary A. Wesenberg, Craig A. Bingman
  • Patent number: 8246944
    Abstract: This invention refers to an immunotherapeutic agent based on cell wall fragments from virulent Mycobacterium tuberculosis strains, to a method for obtaining this immunotherapeutic agent, to pharmaceutical formulations containing it and to its use for the preparation of a drug for the combined treatment of tuberculosis in association with other drugs.
    Type: Grant
    Filed: October 29, 2004
    Date of Patent: August 21, 2012
    Assignee: Archivel Farma, S.L.
    Inventors: Pere Joan Cardona Iglesias, Isabel Amat Riera
  • Publication number: 20120128720
    Abstract: Tuberculosis (TB) is a major health problem and currently, the only licensed TB vaccine is Mycobacterium bovis Bacille Calmette-Guerin (M. bovis BCG). In the present invention, mutation of mycobacterial components reportedly involved in phagosome maturation inhibition was evaluated for vaccine purposes, as such mutations should result in better vaccine antigen processing and presentation. Thus, BCG mutants in genes coding for ManLAM capping ?-1,2-mannosyltransferases and the PI3P phosphatase SapM were evaluated as TB vaccines in a stringent mouse model. Vaccination with both ManLAM capping mutants and the SapM mutant resulted in significantly longer survival as compared to non-vaccinated mice, whereas vaccination with the parental BCG did not. Moreover, mice vaccinated with the SapM mutant survived significantly longer than mice vaccinated with the parental BCG.
    Type: Application
    Filed: July 28, 2010
    Publication date: May 24, 2012
    Inventors: Nico Callewaert, Anjana Batni, Nele Festjens, Christiane Huygen
  • Patent number: 8163292
    Abstract: A herpes simplex virus is disclosed in which the herpes simplex virus genome comprises a nucleic acid sequence encoding an ING4 polypeptide.
    Type: Grant
    Filed: February 15, 2008
    Date of Patent: April 24, 2012
    Assignee: Virttu Biologics Limited
    Inventors: Joe Conner, Susanne Moira Brown
  • Patent number: 8148136
    Abstract: This invention relates to the protein, Mycobacterium paratuberculosis acylase (mpa) and the gene encoding mpa, which we have identified in the pathogen Mycobacterium paratuberculosis Mptb (also designated Mycobacterium avium subspecies paratuberculosis MAP), and to their use in the diagnosis of Mptb/MAP infections in animals and humans, as well as their use as components of vaccines for the prevention and treatment of diseases caused by Mptb/MAP. The importance of an intact uninterrupted mpa gene as a determinant of pathogenicity in Mptb/MAP is recognized and the invention also provides attenuated strains of normally pathogenic Mptb/MAP and other mycobacteria in which mpa has been inactivated, for use as vaccines.
    Type: Grant
    Filed: March 18, 1999
    Date of Patent: April 3, 2012
    Assignee: HAV Vaccines Limited
    Inventors: John Hermon-Taylor, Timothy John Bull
  • Patent number: 8124068
    Abstract: Immunogenic compositions comprising recombinant attenuated intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens are provided. Exemplary immunogenic compositions include, but are not limited to attenuated recombinant Mycobacteria expressing the major extracellular non-fusion proteins of Mycobacteria and/or other intracellular pathogens. Other embodiments are provided wherein the recombinant attenuated intracellular pathogen is auxotrophic.
    Type: Grant
    Filed: October 19, 2009
    Date of Patent: February 28, 2012
    Assignee: The Regents of the University of California
    Inventors: Marcus A. Horwitz, Gunter Harth, Michael V. Tullius
  • Publication number: 20120045476
    Abstract: The present invention provides live, attenuated Mycoplasma bacteria that exhibit reduced expression of one or more proteins selected from the group consisting of pyruvate dehydrogenase, phosphopyruvate hydratase, 2-deoxyribose-5-phosphate aldolase, and ribosomal protein L35, relative to a wild-type Mycoplasma bacterium of the same species. Also provided are vaccines and vaccination methods involving the use of the live, attenuated Mycoplasma bacteria, and methods for making live attenuated Mycoplasma bacteria.
    Type: Application
    Filed: October 28, 2011
    Publication date: February 23, 2012
    Applicant: Wyeth LLC
    Inventors: Mahesh KUMAR, Muhammad Ayub Khan